Quest Diagnostics (DGX) director acquires 67 shares through dividend reinvestment
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Quest Diagnostics director Vicky B. Gregg reported a small automatic share acquisition. On January 28, 2026, she acquired 67 shares of common stock at $183.513 per share through a broker-administered dividend reinvestment plan, bringing her direct holdings to 17,104 shares. The transaction was voluntarily reported early on Form 4, even though it was eligible for deferred reporting on Form 5 under Rule 16a-6.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gregg Vicky B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| L | Common Stock | 67 | $183.513 | $12K |
Holdings After Transaction:
Common Stock — 17,104 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Quest Diagnostics (DGX) disclose for Vicky B. Gregg?
Quest Diagnostics director Vicky B. Gregg reported acquiring 67 shares of common stock via a dividend reinvestment plan at $183.513 per share. This routine transaction slightly increased her direct ownership and was voluntarily reported early on Form 4.
How was the Quest Diagnostics (DGX) insider transaction executed for Vicky B. Gregg?
The transaction was executed through a dividend reinvestment plan administered by the director’s broker. Dividends were automatically used to acquire 67 additional Quest Diagnostics shares, increasing her direct holdings without a separate open-market trade.
Why was the Quest Diagnostics (DGX) insider transaction reported on Form 4 instead of Form 5?
The dividend reinvestment transaction was eligible for deferred reporting on Form 5 under SEC Rule 16a-6, but the reporting person chose to disclose it early on Form 4, providing more timely transparency about the incremental share acquisition.
Does the Quest Diagnostics (DGX) filing indicate a buy or sell by Vicky B. Gregg?
The filing indicates an acquisition, not a sale. Director Vicky B. Gregg received 67 additional Quest Diagnostics shares through a dividend reinvestment plan, increasing her direct ownership to 17,104 shares following the automatic transaction.